Renaissance Capital logo

CRVS News

Renaissance Capital's 1Q16 US IPO Market Review

EDIT

The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing shareholders. The resulting low tradable float also helped to prop up performance, and IPOs averaged a return of 25%, even...read more

US IPO Weekly Recap: Small-cap biotech ends slowest Q1 since 2009

CRVS

  • In a week shortened by Good Friday, there was one biotech pricing and one initial filing.
  • The first quarter, marked by the least amount of IPO activity since the 1Q 2009, comes to a conclusion next week. Quarter to date, there have been 8 IPOs, all health care, that have raised $667 million.
  • MGM Growth Properties became...read more

Corvus prices IPO at $15, the low end of the range

CRVS

Corvus Pharmaceuticals, which is developing checkpoint inhibitors to treat solid tumors, raised $71 million by offering 4.7 million shares at $15, the low end of the range of $15 to $17. Corvus Pharmaceuticals plans to list on the Nasdaq under the symbol CRVS. Credit Suisse and Cowen & Company acted as lead managers on the deal....read more

Week ahead: One pre-sold biotech IPO during a short holiday week

CRVS

Corvus Pharmaceuticals is the only IPO on the calendar during the shortened holiday week. Since reaching a year-to-date low on February 11, the S&P 500 has gained 12%, while the market cap-weighted Renaissance IPO Index has surged 19%. The VIX Volatility Index has fallen to about 14, its lowest point since August 2015, and its third week in a row comfortably below...read more